<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6906">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017014</url>
  </required_header>
  <id_info>
    <org_study_id>P15-759</org_study_id>
    <nct_id>NCT03017014</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions</brief_title>
  <acronym>LEA</acronym>
  <official_title>Assessing Long-term Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions-LEA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate long-term effectiveness of adalimumab in
      pediatric participants starting a treatment for Crohn's disease in real life conditions,
      namely to describe the time to loss of clinical benefit in a time to event approach. Main
      secondary objectives are to describe growth and pubertal development and to describe
      long-term safety. The participants will be followed-up up to 10 years.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2017</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to loss of clinical benefit</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Loss of clinical benefit will be defined as one of the following:
Loss of efficacy leading to adalimumab discontinuation or
Introduction / reinforcement of other immunosuppressants (ratio dose/weight) or
Introduction / reinforcement of corticosteroids (ratio dose/weight; reinforcement of corticosteroids are allowed within the 4 first months after start of adalimumab)
Introduction of enteral nutrition
CD-related surgery, discontinuation of adalimumab due to adverse event, death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weighted Pediatric Crohn's Disease Activity Index (PCDAI)</measure>
    <time_frame>From Month 0 to 12 years</time_frame>
    <description>The Pediatric Activity Index (PCDAI) has become the standard outcome measure in pediatric Crohn's disease (CD) clinical research. The Weighted Pediatric Crohn's Disease Activity Index (wPCDAI) was developed to add weight to the items in the PCDAI and make it more feasible. In the wPCDAI, growth velocity, abdominal examination, and hematocrit are removed. The wPCDAI score can range from 0-125, with higher signifying severe disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical remission</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Clinical remission is weighted PCDAI &lt; 12.5 or Harvey-Bradshaw index (HBI) &lt;5. Rate of clinical remission will be described at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of steroid-free remission</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Steroid-free remission is defined as weighted PCDAI &lt; 12.5 or HBI &lt;5 and no daily intake of prednisone (whatever the route). Rate of steroid-free remission will be described at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in wPCDAI &gt;= 37.5</measure>
    <time_frame>From Month 0 to 12 years</time_frame>
    <description>A change in wPCDAI &gt;= 37.5 indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Mucosal healing</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Mucosal healing is assessed using Simple Endoscopic Score for Cronh's Disease (SES-CD) score (0 or 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving mucosal healing at each time point</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Mucosal healing is assessed using SES-CD score (0 or 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with fistula remission (in participants with fistulizing CD at entry)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Fistula remission is defined as closure for at least 2 consecutive visits of all fistulae that were draining at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with steroid-free clinical remission at each time point</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>The proportion of participants with steroid-free clinical remission is assessed at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with steroid tapering at each time point (steroids daily dosing lower than at baseline)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>The proportion of participants with steroid tapering i.e., steroids daily dosing lower than at baseline (week 0) is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with immunomodulator-free clinical remission at each time point</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>The proportion of participants with immunomodulator-free clinical remission is assessed at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with dose escalation (dose and/or frequency of injections)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Dosing and/or frequency of injections is monitored to assess dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median percent change from baseline in high sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>From Month 0 to 12 years</time_frame>
    <description>The median percent change from baseline in hs-CRP is assessed at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median percent change from baseline in C-reactive protein (CRP)</measure>
    <time_frame>From Month 0 to 12 years</time_frame>
    <description>The median percent change from baseline in CRP is assessed at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median percent change from baseline in calprotectin</measure>
    <time_frame>From Month 0 to 12 years</time_frame>
    <description>The median percent change from baseline in calprotectin us assessed at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height z-score</measure>
    <time_frame>From Month 0 to 12 years</time_frame>
    <description>Growth is assessed by monitoring changes in height z-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight z-score</measure>
    <time_frame>From Month 0 to 12 years</time_frame>
    <description>Growth is assessed by monitoring changes in weight z-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tanner's staging</measure>
    <time_frame>From Month 0 to 12 years</time_frame>
    <description>Tanner's staging is used to assess growth and pubertal development.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with CD-related surgery</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>CD-related surgery includes subtotal colectomy with ileorectostomy, colectomy with ileo-anal pouch, Koch pouch, ileostomy, small bowel resection, and etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of all-cause hospitalizations</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Hospitalization will be determined from the health care utilization information.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of CD-related hospitalizations</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Hospitalization will be determined from the health care utilization information.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of CD- or drug-related hospitalizations</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Hospitalization will be determined from the health care utilization information.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of infectious events</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>The incidence rate of serious and non-serious opportunistic infections is assessed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Pediatric participants receiving adalimumab</arm_group_label>
    <description>Pediatric participants receiving adalimumab for CD in real-life conditions.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are children and adolescents with Crohn's disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With confirmed diagnosis of Crohn's disease

          -  Adalimumab-naïve patient (a patient having received an anti-TNF other than adalimumab
             may enter the study)

          -  Starting a treatment with adalimumab

          -  Guardian capable of and willing to grant authorization for use/disclosure of data
             collected and patient able to comply with the requirements of the study protocol.

        Exclusion Criteria:

          -  Participants with a history of treatment with adalimumab

          -  Participants enrolled in a concomitant interventional clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérick Girard, MD</last_name>
    <role>Study Director</role>
    <affiliation>medical department - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abdelhak Amara-Korba, MD</last_name>
    <phone>+33 145609200</phone>
    <email>abdelhak.amarakorba@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lidwine Jousse</last_name>
    <phone>+33 145603872</phone>
    <email>lidwine.jousse@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152665</name>
      <address>
        <city>Angers Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152665, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154197</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154197, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154620</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154620, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157926</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157926, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152667</name>
      <address>
        <city>Bron Cedex 09</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152667, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152668</name>
      <address>
        <city>Bron Cedex 09</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152668, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155465</name>
      <address>
        <city>Caen Cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155465, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152664</name>
      <address>
        <city>Clermont Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152664, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154621</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154621, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155464</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155464, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152663</name>
      <address>
        <city>Montivillier</city>
        <zip>76290</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152663, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153658</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153658, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152837</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152837, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 157092</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 157092, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152669</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152669, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152666</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152666, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152830</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152830, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152838</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152838, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152730</name>
      <address>
        <city>Rennes Cedex 2</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152730, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 158688</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 158688, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152670</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152670, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153251</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153251, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152831</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152831, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152729</name>
      <address>
        <city>Vandoeuvre Les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152729, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 9, 2017</lastchanged_date>
  <firstreceived_date>January 9, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Humira®</keyword>
  <keyword>Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
